anti- TREM1 antibody

Background

Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily receptor predominantly expressed on myeloid cells, such as neutrophils, monocytes, macrophages, and dendritic cells. TREM1 is recognized for its role in amplifying inflammatory responses during infections and other inflammatory conditions, and it plays a significant part in innate immune regulation. TREM1 is a potent activator of inflammatory responses and is known to amplify signaling from pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). Through these amplifying actions, TREM1 enhances the immune system’s ability to clear pathogens but also has the potential to contribute to pathological inflammation. Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily receptor predominantly expressed on myeloid cells, such as neutrophils, monocytes, macrophages, and dendritic cells. TREM1 is recognized for its role in amplifying inflammatory responses during infections and other inflammatory conditions, and it plays a significant part in innate immune regulation. TREM1 is a potent activator of inflammatory responses and is known to amplify signaling from pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). Through these amplifying actions, TREM1 enhances the immune system’s ability to clear pathogens but also has the potential to contribute to pathological inflammation. TREM1 activation is linked with inflammatory cytokine production, chemotaxis, and cellular responses involved in pathogen clearance. In addition to pathogen responses, TREM1 is implicated in sterile inflammation, where it is upregulated during non-infectious inflammation, such as that observed in autoimmune diseases, cancer, and tissue damage. Its role in amplifying inflammatory cascades makes TREM1 a focal point for research into immune regulation and as a therapeutic target for controlling inflammation-related diseases.